Innate Pharma SA
F:IDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
F:IDD
|
FR |
|
S
|
Sparebank 1 SMN
OSE:MING
|
NO |
|
infinitii ai inc
OTC:CDTAF
|
CA |
|
A
|
Adtran Networks SE
XMUN:ADV
|
DE |
Earnings Calls
Last Earnings Call
Lacutamab: The Sobi partnership has closed and the Phase III TELLOMAK-3 study has been initiated; the first patient is expected in Q1 2027, with an accelerated-approval filing planned for H2 2027.
IPH4502: Innate reported preliminary anti-tumor activity, including objective responses, and a favorable safety profile to date. Initial Phase I data are planned for November 18, 2026.
Monalizumab: Enrollment in the 1,051-patient PACIFIC-9 Phase III study is complete, and results are expected in H2 2026.
Funding: The $75 million Sobi upfront payment and EUR 30 million equity offering are expected to extend the cash runway through the end of Q1 2028.
Pricing: U.S. payer research indicated a potential lacutamab price of $500,000 to $625,000 per patient per year; management said the range would be supported by clinical data and an expected NCCN listing.